EMERYVILLE, Calif.--(BUSINESS WIRE)--Metagenomi, a genetic medicines company with a versatile portfolio of wholly owned, next-generation gene editing systems, has been named as one of Fast Company’s 16th Annual World’s Most Innovative Companies. Metagenomi is leading a new wave of genetic medicines companies working to translate powerful next-generation gene editing systems into therapies, with the goal of correcting the underlying disease-causing gene. Metagenomi has discovered more than 20,000 editing systems and uses high-throughput genome screening, AI-based cloud computing, and protein engineering to create optimized gene editing tools matched to specific disease targets.
“It is an honor to be recognized as one of the most innovative companies by Fast Company for our work in developing the largest library of next-generation gene editing systems that fuel our pipeline of novel genetic medicines,'' said Brian C. Thomas, Metagenomi Founder and CEO. “We set out to be a disruptor in the gene editing space, leveraging our massive database of genomes from uncultivated organisms to build gene editing tools beyond the standard, first generation CRISPR-cas9 enzyme. Our systems are highly efficient, precise, and can broadly target any codon in the human genome. What drives us is the curative potential that gene editing therapies bring. Gene editing is a revolution that will allow us to address a wide range of diseases affecting millions of patients worldwide who today have few treatment options.”
Fast Company’s World’s Most Innovative Companies list recognizes profound products, services and initiatives poised to have transformative impact. The list and coverage span dozens of industries, themes, and regions, and stands as the defining record of the future of business.
In other recognitions of its impact in the life sciences industry, Metagenomi was named to the 2022 Endpoints 11, which recognizes the top private biotechnology companies that are pushing the envelope in drug development. Furthermore, Jian Irish, President and Chief Operating Officer of Metagenomi, was named by Endpoints News as one of its 2022 Women in Biopharma, a list of extraordinary women engaged in drug research and development worldwide.
Metagenomi is a gene editing company committed to developing potentially curative therapeutics by leveraging a proprietary toolbox of next-generation gene editing systems to accurately edit DNA where current technologies cannot. Our metagenomics-powered discovery platform and analytical expertise reveal novel cellular machinery sourced from otherwise unknown organisms. We adapt and forge these naturally evolved systems into powerful gene editing systems that are ultra small, extremely efficient, highly specific and have a decreased risk of immune response. These systems fuel our pipeline of novel medicines. Our goal is to revolutionize gene editing for the benefit of patients around the world. For more information, please visit https://metagenomi.co.